Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on August 6, 2013. The filing serves to announce the company's financial results for the second quarter ended June 30, 2013.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached earnings press release for comparative analysis.
Guidance, Outlook, and Risks
The document does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release dated August 6, 2013) for actual financial figures.
- Verify the specific revenue and net income figures for the quarter ended June 30, 2013.
- Check for any updated financial guidance or operational milestones mentioned in the press release.
- Confirm the status of the company's cash position and debt obligations as detailed in the full earnings report.